Aslan Aygün

Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

Levent Kabasakal, Mohammad Abuqbeitah, Aslan Aygün et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2015 · 208 citations

Medicine, Oncology, Pharmacology +17

Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging

Levent Kabasakal, Emre Demirci, Meltem Ocak et al. · Nuclear Medicine Communications · 2015 · 137 citations

Medicine, Nuclear Medicine, Radiology +17

Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Levent Kabasakal, Türkay Toklu, Nami Yeyin et al. · Molecular Imaging and Radionuclide Therapy · 2017 · 83 citations · Full text

Medicine, Oncology, Pharmacology +17

The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels

Levent Kabasakal, Emre Demirci, Jamal Nematyazar et al. · Nuclear Medicine Communications · 2016 · 40 citations

Medicine, Nuclear Medicine, Radiology +17

Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer

Meltem Ocak, Emre Demirci, Levent Kabasakal et al. · Nuclear Medicine Communications · 2013 · 29 citations

Medicine, Nuclear Medicine, Radiology +17